摘要
目的分析来那度胺联合小剂量地塞米松治疗多发性骨髓瘤的临床效果。方法选择2018年1月至2022年12月我院收治的50例多发性骨髓瘤患者作为研究对象,以地塞米松的使用剂量差异将其分为A组(来那度胺联合大剂量地塞米松治疗)和B组(来那度胺联合小剂量地塞米松治疗),每组25例。比较两组的治疗效果。结果两组的治疗总有效率比较,差异无统计学意义(P>0.05)。治疗后,两组的血红蛋白(HGB)、骨钙素N端中分子片段(N-MID)、骨生长蛋白(BGP)水平及骨密度(BMD)均升高,血沉(ESR)、β2微球蛋白(β2-MG)、肌酐(Cre)、白细胞介素-1β(IL-1β)、白细胞介素-8(IL-8)、血管内皮生长因子(VEGF)、表皮细胞生长因子(EGF)及β-胶原降解产物(β-CTX)水平均降低,且B组优于A组(P<0.05)。B组治疗期间的不良反应总发生率低于A组(P<0.05)。结论来那度胺联合小剂量地塞米松治疗多发性骨髓瘤可有效改善肝肾功能,调节骨代谢,且不会增加不良反应,从而取得理想的疗效。
Objective To analyze the clinical effect of lenalidomide combined with low-dose dexamethasone in the treatment of multiple myeloma.Methods A total of 50 patients with multiple myeloma admitted in our hospital from January 2018 to December 2022 were selected as the research objects,according to the dose difference of dexamethasone,the patients were divided into group A(lenalidomide combined with high-dose dexamethasone)and group B(lenalidomide combined with low-dose dexamethasone),with 25 cases in each group.The therapeutic effects of the two groups were compared.Results There was no significant difference in the total effective rate of treatment between the two groups(P>0.05).After treatment,the hemoglobin(HGB),molecular fragment of osteocalcin N terminal(N-MID),bone growth protein(BGP)levels and bone mineral density(BMD)increased,the levels of erythrocyte sedimentation rate(ESR),β2-microglobulin(β2-MG),creatinine(Cre),interleukin-1β(IL-1β),interleukin-8(IL-8),vascular endothelial growth factor(VEGF),epidermal growth factor(EGF)andβ-C-terminal telopeptide of type-Ⅰcollagen(β-CTX)decreased in both groups,and those in the group B were better than the group A(P<0.05).The total incidence of adverse reactions during treatment in the group B was lower than that in the group A(P<0.05).Conclusion Lenalidomide combined with low-dose dexamethasone in the treatment of multiple myeloma can effectively improve liver and kidney function and regulate bone metabolism,without increasing adverse reactions,so as to achieve ideal curative effect.
作者
夏雷
吴诗
XIA Lei;WU Shi(Hematology Department,the First People's Hospital of Jintan,Changzhou 213200,China;Oncology Department,the First People's Hospital of Jintan,Changzhou 213200,China)
出处
《临床医学研究与实践》
2024年第24期42-45,共4页
Clinical Research and Practice
作者简介
夏雷(1987—),男,主治医师,硕士。研究方向:多发性骨髓瘤。
